Valneva's (VALN) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Valneva (NASDAQ:VALN - Free Report) in a research note published on Friday,Benzinga reports. HC Wainwright currently has a $17.00 target price on the stock.

Valneva Stock Performance

NASDAQ:VALN traded down $0.36 during trading hours on Friday, hitting $7.07. 20,330 shares of the company were exchanged, compared to its average volume of 26,146. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. Valneva has a 52-week low of $3.62 and a 52-week high of $9.50. The stock has a market capitalization of $574.52 million, a price-to-earnings ratio of -54.38 and a beta of 1.93. The company's 50 day moving average price is $6.45 and its 200-day moving average price is $5.59.

Valneva (NASDAQ:VALN - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.32). The company had revenue of $56.48 million for the quarter, compared to analysts' expectations of $55.64 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. As a group, research analysts forecast that Valneva will post 0.13 earnings per share for the current year.

Remove Ads

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. Wells Fargo & Company MN raised its holdings in shares of Valneva SE (NASDAQ:VALN - Free Report) by 14.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 246,766 shares of the company's stock after acquiring an additional 30,859 shares during the period. Wells Fargo & Company MN owned approximately 0.30% of Valneva worth $1,079,000 at the end of the most recent quarter. 11.39% of the stock is currently owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.